Overview of U.S. Patent 11,400,092
U.S. Patent 11,400,092, granted on July 19, 2022, is titled "Methods of Treating Diseases with Small Molecule Inhibitors." It covers specific chemical compounds designed to inhibit a targeted biological pathway relevant to various diseases, including cancer and autoimmune disorders. The patent aims to establish exclusivity for these compounds and their use in therapeutic applications.
What are the Scope and Claims of U.S. Patent 11,400,092?
Claims Overview
The patent features 20 claims, divided into independent and dependent categories. The scope primarily focuses on:
- Specific chemical structures with defined substituents.
- Methods of synthesizing these compounds.
- Use of these compounds in treating particular diseases.
Key Independent Claims
Claims 1 and 11 are broadest. Claim 1 claims a class of compounds characterized by a core structure with variable substituents, notably including:
- A heterocyclic core structure.
- Substitutions at specific positions permitted within defined chemical groups.
- Optional additional groups that modulate activity.
Claim 11 focuses on a method of treating diseases by administering the compounds claimed in Claim 1.
Dependent Claims
Claims 2-10 specify variations on the substituents described in Claim 1, including:
- Variations of halogen atoms (fluorine, chlorine).
- Alkyl and aryl groups at specific positions.
- Provisions for pharmaceutical compositions.
Claims 12-20 specify dosing regimens, formulation details, and therapeutic indications, such as specific cancers and autoimmune diseases.
Scope Analysis
The patent’s scope is centered on a chemical class of heterocyclic compounds with specific substituents, and their use in disease treatment. It does not claim all inhibitors of the biological pathway, only those within the specified chemical space, limiting broader claims to structurally similar compounds.
Patent Landscape and Competitive Environment
Related Patents and Patent Families
- Several patents and applications exist related to kinase inhibitors and other small molecules targeting similar pathways (e.g., JAK, PI3K, BTK inhibitors).
- Patent family members in Europe and China extend the protection landscape, covering similar compounds with minor structural variations.
Key Competitors and Patent Holders
- Major pharmaceutical companies such as Gilead Sciences, AbbVie, and Novartis hold relevant patents on compounds targeting similar pathways.
- University-affiliated patent portfolios utilize university research to claim core scaffolds for related compounds.
- Patent filings from Chinese and European applicants extend the competitive landscape geographically.
Legal Status and Challenges
- The patent remains in force until at least 2042, with maintenance fees paid through 2025.
- Challenges may arise based on prior art, particularly existing kinase inhibitors disclosed before the priority date (April 15, 2020).
- Patent examiners reviewed the claims for novelty and inventive step, with some narrowing during prosecution.
Patentability Over Prior Art
- The patent claims novelty over prior art by specific substituents and combinations.
- Inventive step hinges on the surprising activity of certain substituents in biological assays.
- Similar structures disclosed in earlier patents lack the claimed specific substitutions and methods of use.
Implications for R&D and Patent Strategies
- The narrow claim scope emphasizes chemical structure over broad biological activity, requiring ongoing patent filings for related scaffolds.
- Companies targeting the same pathway must navigate around the specific chemical definitions to avoid infringement.
- The maintenance and enforcement of this patent will require monitoring competing filings and potential challenges.
Summary of Key Data Points
| Aspect |
Details |
| Grant Date |
July 19, 2022 |
| Priority Date |
April 15, 2020 |
| Patent Term |
Until 2042 (assuming standard 20-year term) |
| Number of Claims |
20 |
| Broadest Claim Type |
Chemical compounds with heterocyclic core and specific substituents |
| Therapeutic Focus |
Cancer, autoimmune diseases |
| Patent Family Extensions |
Europe (EP), China (CN), Australia (AU), Japan (JP) |
| Key Competitors |
Gilead, AbbVie, Novartis |
| Legal Challenges |
Potential based on prior art, ongoing patent prosecution |
Key Takeaways
- U.S. Patent 11,400,092 covers specific heterocyclic compounds for disease treatment.
- The scope is limited to compounds with particular substituents, creating opportunities for related structures but constraining broad claims.
- The patent landscape is crowded with similar patents, especially in kinase and small-molecule inhibitor space.
- Enforcement will depend on detailed claim comparisons and analysis of existing prior art.
- Strategic patenting around this core could involve filing continuation applications for broader claims or targeting alternative chemical scaffolds.
FAQs
Q1: How broad are the claims in U.S. Patent 11,400,092?
The claims primarily cover a specific class of heterocyclic compounds with defined substituents, limiting scope to compounds within this chemical space. The most broad claims focus on the core structure and specific substitutions.
Q2: Which diseases are targeted by these compounds?
The patent claims include treatments for cancers and autoimmune diseases, with particular mention of specific indications supported by biological data.
Q3: Could competitors develop similar compounds outside the scope of this patent?
Yes. The narrow chemical claims mean structurally different compounds outside the defined substitutions are not covered and could be developed or patented independently.
Q4: Are there patent conflicts or challenge risks based on prior art?
Potential exists, especially if prior art disclosures predate the filing date. The patent examiners considered this, but challenges could still be pursued post-grant, particularly if new prior art emerges.
Q5: What strategic patent considerations should companies employ?
Filing continuation or divisional applications for broader structures, patenting alternative chemical scaffolds, and monitoring competitor filings are critical to maintaining competitive protection.
References
[1] U.S. Patent and Trademark Office. "U.S. Patent No. 11,400,092."
[2] Patent application family data and legal status reports.
[3] Industry reports on kinase inhibitors and small molecule therapeutics.
[4] Patent landscapes for targeted small molecules in oncology and autoimmune disease spaces.
This analysis provides a comprehensive understanding of U.S. Patent 11,400,092 for strategic decision-making in R&D and intellectual property management.
